have demonstrated this remarkable potential. What sets us apart is our off-the-shelf, non-invasive treatment: healthy human adult blood-derived SMS cells delivered directly to the lungs via a simple nebulizer. With 16 patents filed and 6 granted, we are currently advancing our first-in-human phase 1 safety trial, bringing hope to patients worldwide.